Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:37:37.078Z.
Calculation as of: 2026-10-06T20:37:37.078Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16e56446a21e9a843cc6c6ff7300520dfb83e67729e55a1fc0216220cdac96b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$264.38M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.29M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.50M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.04M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.73M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oaktree Acquisition Corp. II (OACC) | $264.51M | N/A | N/A | N/A | N/A |
| ProCap Acquisition Corp (PCAP)vs › | $264.47M | N/A | N/A | N/A | N/A |
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)vs › | $264.38M | N/A | N/A | N/A | N/A |
| Soren Acquisition Corp. (SORN)vs › | $263.53M | N/A | N/A | N/A | N/A |
| Hawthorn Bancshares, Inc. (HWBK)vs › | $265.95M | 2.28 | 2.18 | 1.93 | 1.90 |
| Thunder Bridge Capital Partners V L (TBCVU)vs › | $266.29M | N/A | N/A | N/A | N/A |
| Translational Development Acquisition Corp. (TDAC)vs › | $266.50M | N/A | N/A | N/A | N/A |
| Cantor Equity Partners V, Inc. Class A Ordinary Shares (CEPV)vs › | $262.04M | N/A | N/A | N/A | N/A |
| AMR Resources Acquisition Corp Class A Ordinary Shares (AMAC)vs › | $261.73M | N/A | N/A | N/A | N/A |
| GigCapital8 Corp. (GIW)vs › | $261.45M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
